GSK Announces Nominations Committee Board Changes

Glaxo SmithKline (GSK) has announced that Sir Philip Hampton has been appointed Chairman of the Nominations Committee, with effect from today (January 27). He replaces Sir Christopher Gent, who will continue to serve as a member of the Committee for the remainder of his tenure on the Board.

In addition, Ms Lynn Elsenhans has also been appointed a member of the Committee.

The membership of the Nominations Committee is now:

Sir Philip Hampton - CommitteeChairman Designate

Sir Christopher Gent - Chairman
 
Professor Sir Roy Anderson - Scientific & Medical Expert
 
Lynn Elsenhans - Non Executive Director
 
Judy Lewent - Audit & Risk Committee Chairman
 
Sir Deryck Maughan - Senior Independent Director
 
Tom de Swaan - Remuneration Committee Chairman